JMDC Inc (6JM) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of JMDC Inc €21.56, price €19.00, upside +13.5%, quality 57 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
In Frankfurt, only 0 of the last 21 trading days (30 days) had any turnover. On the other days the price is an indicative quote without trading, so we do not list this stock in the radar. It stays reachable through search.
JIBroad dataSep 30, 2026
JMDC Inc
6JM · F
UndervaluedQuality growthThe stock appears undervalued with acceptable quality.
Watch JMDC Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 30, 2026.
How to read this chart
48‑month range €13.00 – €40.09 · fair‑value band €13.27 – €34.13 · the €19.00 price screens below the €21.56 fair value. Dashed = 300-day average. As of Sep 30, 2026.
Follow JMDC in your weekly email
Every Wednesday you see whether JMDC is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
JMDC Inc. provides medical statistics data services in Japan. It operates through two segments: Health Big Data and Telemedicine.
Show more
JMDC Inc. provides medical statistics data services in Japan. It operates through two segments: Health Big Data and Telemedicine. The company offers big data services for medical field, including WEB tool, analytic, raw data provision, and publication support services; data provision and aggregation, consulting, and solution development services; supporting health business for health insurance unions and local government health services; health data platform; and medical institution support services. It also provides JMDC Claims Database, an epidemiological receipt database that has accumulated receipts, including inpatient, outpatient, and dispensing, as well as medical examination data received from multiple health insurance associations. It serves doctors, patients, medical institutions, insurers, pharmaceutical companies, life and non-life insurance companies, and research institutions. JMDC Inc. was incorporated in 2002 and is headquartered in Tokyo, Japan. JMDC Inc. is a subsidiary of OMRON Corporation.
Stock analysis
JMDC Inc (6JM) currently trades at €19.00, while our model-based Fair Value estimate is €21.56, implying the stock looks roughly 11.9% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of €17.86 per share, and 3 of the 26 models we run sit above the €19.00 price.
Bear case: the Asset-Based group reads lowest at €4.82, and 23 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: €13.27 (bear) to €34.13 (bull), the price of €19.00 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
JMDC Inc reported revenue of ¥50.5B in FY2026 versus ¥21.8B in FY2022, a compound +23.3%/yr. Reported net income was ¥6.8B in FY2026, compounding +20.1%/yr from FY2022.
Key figures
Market cap €1.2B · P/E ratio 33.3 · P/S ratio 4.47 · EPS (TTM) €0.5700 · Net margin 13.4% · Return on equity 8.6% · Return on assets (EBIT) 6.2% · Operating margin 14.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 31% below its 52-week high and 46% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 13%, 6JM screens cheaper than that median.
Fair Value models
Bear €13.27Fair Value €21.56Bull €34.13
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.95/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+20.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.0%
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in JPY ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in JPY: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+12.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+12.5%
Dividend (yield on the price)0.0%
Profit margin 2022 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.22% → 21%
Growth Forecast
A lot of optimism in the price
The price assumes about as much growth as the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+22.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+15.9%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in JPY, Japan: IMF forecast 2.1% a year to 2030, 1.3% from 2016 to 2025) that is about +20.0% a year for the price and +13.5% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 116 stocks
Beats the industry median on 8/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score57 · Above median
Fair Value upside+8.9% · Above median
Profitability
Return on equity (TTM)8.6% · Above median
Return on assets4.5% · Above median
Net margin (TTM)13.2% · Top 25%
Operating margin (TTM)14.5% · Top 25%
Growth and dividend
Revenue growth17.5% · Above median
Dividend yield (TTM)91.4% · Top 25%
Balance sheet
Debt / equity0.43× · Highest 25%
Valuation Multiplesvs Health Information Services median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "JMDC Inc Fair Value". https://www.fairvalue-calculator.com/stock/6JM
Frequently asked questions
Is JMDC Inc (6JM) overvalued or undervalued?
As of Sep 30, 2026, our model estimates a fair value of €21.56 versus a price of €19.00, about +13% upside (undervalued).
What is the fair value of 6JM?
Our model-based fair value for JMDC Inc is €21.56 (as of Sep 30, 2026), built from audited fundamentals. The current price: €19.00.
What is the quality score of 6JM?
JMDC Inc has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for JMDC Inc (6JM)?
Our model-based price target is the fair value of €21.56 (as of Sep 30, 2026) from 26 valuation models. Cautious scenario €13.27, optimistic scenario €34.13. It is a calculation from audited fundamentals, not an analyst target.
What is the JMDC Inc stock forecast for 2026?
Our models put fair value at €21.56, about +13% upside versus a price of €19.00 (undervalued). Cautious scenario €13.27, optimistic scenario €34.13. The calculation is refreshed regularly with new filings.
What is the revenue of JMDC Inc (6JM)?
JMDC Inc reported trailing-twelve-month revenue of about ¥52.3B (latest available figure, as of Sep 30, 2026).
What growth is priced into JMDC Inc (6JM)?
For today's price to be fair in a discounted-cash-flow model, JMDC Inc would have to grow free cash flow by +22.5 % per year for five years (discount rate 10.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +23.3 % per year. As of Sep 30, 2026.
What discount rate (WACC) does the fair value of 6JM use?
Our models discount JMDC Inc at 10.5 %: a base by market capitalisation (small), damped by beta 0.81, country premium for Germany. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For JMDC Inc that is +22.5 % per year a year over ten years, using the same discount rate (10.5 %) and the same formula as our fair value.
How much growth has JMDC Inc (6JM) delivered so far?
Over the past 4 years revenue at JMDC Inc grew +23.3 % a year. The price currently implies +22.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of JMDC Inc (6JM) growing?
The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into JMDC Inc (+22.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of JMDC Inc (6JM)?
The free-cash-flow yield on the price is 2.97 %: that much free cash flow JMDC Inc produces per unit of market value. When it exceeds the discount rate of our models (10.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of JMDC Inc (6JM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For JMDC Inc it is €21.56 per share (as of Sep 30, 2026), against a price of €19.00. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is JMDC Inc stock overvalued or undervalued in 2026?
As of Sep 30, 2026, 6JM trades below its calculated fair value: price €19.00, fair value €21.56, a gap of about +13% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6JM?
No. The price is what the market pays today (€19.00); the fair value is what the company's own numbers justify (€21.56). For JMDC Inc the two are €2.56 per share apart. That gap is exactly why we show both numbers side by side.
How much is JMDC Inc worth?
The market values JMDC Inc at about €1.2B (market capitalisation, as of Sep 30, 2026). Per share that is €19.00; our models calculate a fair value of €21.56 per share.
What do the bullish and bearish scenarios say about 6JM?
Our models span a range for JMDC Inc: cautious scenario €13.27, base €21.56, optimistic €34.13 per share (as of Sep 30, 2026, price €19.00). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6JM?
JMDC Inc trades at a price-to-earnings ratio of 33.3 (as of Sep 30, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €21.56 is built from several models across several years. Other multiples: P/B 2.8, P/S 4.4, EV/EBITDA 16.8.
How solid is the balance sheet of JMDC Inc (6JM)?
Balance-sheet figures for JMDC Inc (as of Sep 30, 2026): return on equity 8.6%, debt of 0.43 per unit of equity. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is 6JM from its 52-week high?
JMDC Inc trades at €19.00, about 31% below its 52-week high of €27.45 and 46% above the low of €13.00 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of €21.56 is for.
Which stocks are comparable to JMDC Inc?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is JMDC Inc stock attractive at the current price?
The data as of Sep 30, 2026: price €19.00, calculated fair value €21.56 (+13%), Quality Score 57/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6JM calculated?
We run JMDC Inc through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €21.56, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. JMDC Inc currently trades 12 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of JMDC Inc (6JM)?
The closing price on Oct 1, 2026 was €19.00. Our model-based fair value is €21.56, about +13% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with JMDC Inc right now?
A fairly wide model range (€13.27 to €34.13) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Key figures of JMDC Inc
How large is the market capitalisation of JMDC Inc (6JM)?
The market capitalisation of JMDC Inc is €1.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of JMDC Inc (6JM)?
The price-to-sales ratio of JMDC Inc is 4.47 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of JMDC Inc (6JM)?
Earnings per share at JMDC Inc are €0.5700 (price ÷ EPS = P/E 33.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of JMDC Inc (6JM)?
The net margin of JMDC Inc is 13.4% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of JMDC Inc (6JM)?
The return on equity (ROE) of JMDC Inc is 8.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of JMDC Inc (6JM)?
On an EBIT basis the return on assets of JMDC Inc is 6.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of JMDC Inc (6JM)?
The operating margin of JMDC Inc is 14.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at JMDC Inc (6JM)?
Revenue at JMDC Inc is growing +17.5% versus a year earlier (3y avg +22.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at JMDC Inc (6JM)?
Earnings per share at JMDC Inc are growing +17.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does JMDC Inc (6JM) carry?
The net debt of JMDC Inc is ¥12.5B (fiscal year 2026, ≈ 1.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch JMDC Inc in the live analysis
One click puts JMDC Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
